Here we show that using the combination of CEA, CA19-9, and CA125 can stratify patients with appendiceal adenocarcinoma into groups with 5-year survival ranging from 97% for those with no tumor markers elevated to 63% for those with all 3 markers elevated (Figure 2D). This evidence concerns the gene MUC16 and appendix adenocarcinoma.